FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002857025> ?p ?o ?g. }

• W3002857025 abstract "HomeJournal of the American Heart AssociationVol. 9, No. 3What Is the Best Mix of Population‐Wide and High‐Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention? Open AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citations ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessReview ArticlePDF/EPUBWhat Is the Best Mix of Population‐Wide and High‐Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention? Valery L. Feigin, MD, PhD, FAAN, FRSNZ, FRAS, Michael Brainin, MD, PhD, Bo Norrving, MD, PhD, Philip B. Gorelick, MD, MPH, Martin Dichgans, MD, Wenzhi Wang, MD, PhD, Jeyaraj Durai Pandian, MD, DM, Sheila Cristina Ouriques Martins, MD, PhD, Mayowa O. Owolabi, DM, FRCP, David A. Wood, MD and Graeme J. Hankey, MD, FRACP Valery L. FeiginValery L. Feigin *Correspondence to: Valery L. Feigin, MD, PhD, FAAN, FRSNZ, FRAS, National Institute for Stroke and Applied Neurosciences, School of Public Health and Psychosocial Studies, Faculty of Health and Environmental Sciences, AUT University, 90 Akoranga Dr, Northcote, Auckland 0627, New Zealand. E‐mail: E-mail Address: [email protected] and Michael Brainin, MD, PhD, Department of Neuroscience and Preventive Medicine, President of the World Stroke Organization, Danube University Krems, Krems, Austria. Email: E-mail Address: [email protected] National Institute for Stroke and Applied Neurosciences, , School of Public Health and Psychosocial Studies, , Faculty of Health and Environmental Sciences, , AUT University, , Auckland, , New Zealand Search for more papers by this author , Michael BraininMichael Brainin *Correspondence to: Valery L. Feigin, MD, PhD, FAAN, FRSNZ, FRAS, National Institute for Stroke and Applied Neurosciences, School of Public Health and Psychosocial Studies, Faculty of Health and Environmental Sciences, AUT University, 90 Akoranga Dr, Northcote, Auckland 0627, New Zealand. E‐mail: E-mail Address: [email protected] and Michael Brainin, MD, PhD, Department of Neuroscience and Preventive Medicine, President of the World Stroke Organization, Danube University Krems, Krems, Austria. Email: E-mail Address: [email protected] Department of Neuroscience and Preventive Medicine, , President of the World Stroke Organization, , Danube University Krems, , Austria Search for more papers by this author , Bo NorrvingBo Norrving Department of Clinical Sciences, , Department of Neurology, , Skåne University Hospital, , Lund University, , Lund, , Sweden Search for more papers by this author , Philip B. GorelickPhilip B. Gorelick Davee Department of Neurology, , Northwestern University Feinberg School of Medicine, , Chicago, , IL Population Health Research Institute, , McMaster University of Health Sciences and Hamilton University, , Hamilton, , Ontario, , Canada Search for more papers by this author , Martin DichgansMartin Dichgans Institute for Stroke and Dementia Research (ISD), , University Hospital, , Ludwig‐Maximilians‐Universität LMU, , Munich, , Germany Munich Cluster of Systems Neurology (SyNergy), , Munich, , Germany Search for more papers by this author , Wenzhi WangWenzhi Wang Beijing Neurosurgical Institute, , Capital Medical University, , Beijing, , People's Republic of China National Office for CVD Prevention and Control, , National Health Commission, , Beijing, , China Search for more papers by this author , Jeyaraj Durai PandianJeyaraj Durai Pandian Department of Neurology, , Christian Medical College, , Ludhiana, , Punjab Search for more papers by this author , Sheila Cristina Ouriques MartinsSheila Cristina Ouriques Martins Brazilian Stroke Network President, , Hospital de Clínicas de Porto Alegre, , Hospital Moinhos de Vento, , Porto Alegre, , Brazil Search for more papers by this author , Mayowa O. OwolabiMayowa O. Owolabi Center for Genomic and Precision Medicine, , University of Ibadan, , Ibadan, , Oyo, , Nigeria University College Hospital, , Ibadan, , Oyo, , Nigeria Blossom Center for Neurorehabilitation, , Ibadan, , Nigeria Search for more papers by this author , David A. WoodDavid A. Wood National Heart and Lung Institute, , Imperial College London, , London, , United Kingdom National Institute for Prevention and Cardiovascular Health, , National University of Ireland, , Galway, , Ireland Search for more papers by this author and Graeme J. HankeyGraeme J. Hankey Medical School, , The University of Western Australia, , Perth, , Australia Search for more papers by this author Originally published25 Jan 2020https://doi.org/10.1161/JAHA.119.014494Journal of the American Heart Association. 2020;9:e014494In arguably the most influential public health article ever written, “Sick Individuals and Sick Populations,” Geoffrey Rose1 described and appraised 2 mainstream strategies for primary prevention of disease: (1) the “high‐risk” strategy, where the preventative strategy seeks to identify high‐risk susceptible individuals to offer them some individual protection; and (2) the population “mass” strategy aimed to reduce the mean level of the determinants of disease, and thereby the incidence of disease, in the population as a whole. He concluded that a “high‐risk” strategy is needed only as long as the underlying causes of incidence remain unknown or uncontrollable, and the priority in primary prevention should always be the discovery and control of the causes of incidence to shift the whole distribution of exposure in a favorable direction via a population strategy.For the primary prevention of stroke and cardiovascular disease (CVD), the value of population screening to identify individuals at high risk of CVD was first publicly debated almost 20 years later.2 Jackson et al,3 the proponents of the high‐risk strategies argued that the key for preventing CVD is well‐targeted treatment with safe, inexpensive and effective drugs for patients at high risk and that this approach is more effective than population‐wide interventions, such as reducing salt intake and managing obesity.2, 3 However, it was argued by Capewell,4 the opponent of the high‐risk strategy, that the “high‐risk” approach lacks effectiveness and is associated with low uptake of the screening, inaccuracy of the CVD risk scoring systems in estimating an individual patient's risk, low adherence to treatment, medicalization of individuals, and high cost.2, 4 He warned that perhaps the greatest harm arising from the “high‐risk” strategies is misleading health professionals and politicians into thinking they can tick the box “mission accomplished” (screening completed) and the problem of CVD prevention is solved. Therefore, the best strategy for preventing CVD is policy interventions aimed at reducing key modifiable CVD risk factors across whole populations.2 However, at the time of the debate there was no robust evidence for or against either of these strategies. As the global burden and cost of stroke and CVD5, 6 is increasing, it is timely and necessary to critically review the current strategies of stroke and CVD prevention in light of the available evidence to inform future directions in primary stroke and CVD prevention (see Tables 1 and 2 for “Aims of This Viewpoint” and “Search and Selection Criteria”).Table 1. Aims of This ViewpointTo outline a history of primary stroke and cardiovascular disease (CVD) prevention strategies developmentTo outline advantages and disadvantages of “high‐risk” and population‐wide primary stroke prevention strategiesTo describe current trends in primary stroke preventionTo provide evidence of effects of primary stroke and CVD “high‐risk” and population‐wide prevention strategies on stroke and CVD incidence and/or mortalityTo suggest priorities and funding sources for primary stroke and CVD prevention strategiesTo suggest future directions in primary stroke and CVD prevention strategies and researchTable 2. Search and Selection CriteriaWe also searched MEDLINE, Embase, Google Scholar, and the Cochrane Library, as well as the internet (using Google and other search engines), for primary stroke and CVD prevention research published between January 1970 and September 2019 using the following key words in title or abstract: “stroke,” “cerebrovascular disease,” “isch(a)emic heart disease,” or “cardiovascular disease” AND “prevention,” “cost,” “guidelines,” “tax or taxation,” “trial,” “incidence,” “prevalence,” “mortality,” “burden,” or “outcomes.” We concentrated on randomized controlled trials and population‐based studies. Additionally, we manually searched the reference lists of relevant publications and consulted with experts in stroke, CVD, and other relevant stakeholders, to complement the electronic searches.Current Trends in Primary Prevention StrategiesOver the past 2 decades, the advent of new and more accurate CVD risk scoring systems7, 8, 9, 10, 11 has shifted focus from population‐wide prevention strategies to more medicalized “high‐risk” strategies.11 Despite the lack of robust evidence for cost and medical effectiveness of the “high‐risk” approach in terms of the reduction of stroke and CVD incidence on a population level,12, 13 virtually all guidelines on CVD prevention stress the importance of a total CVD risk‐based screening approach14, 15, 16, 17, 18, 19 and this strategy has become the focus of public health policy in several countries, including New Zealand,17 Australia,18 the United Kingdom,20 and China.21 The “high‐risk” strategy is also advocated by the American Heart Association (AHA) in the Million Heart Cardiovascular Risk Reduction Programme22 and the identification of individuals at risk was emphasized as the focus of the national primary CVD prevention strategy in 2010.23In the United States, the AHA has emphasized both the high‐risk strategy and population or mass approach. For example, the AHA has launched the Million Hearts Initiative targeting improvement in both clinical preventative practice and community prevention.24, 25, 26 The Million Hearts Initiative represents a partnership with a number of organizations including the US Centers for Disease Control and Prevention. The key components of the initiative are to improve clinical prevention by increasing appropriate aspirin use, hypertension control and cholesterol control, reducing smoking, aligning health information technology with key metrics across healthcare systems, advocating for clinical innovations in care, strengthening community prevention in the domains of tobacco and smoking control at state and local levels, supporting evidence‐based interventions for preventative control, and improving overall nutrition in the population. Furthermore, the AHA has launched a Life's Simple 7 community campaign to improve cardiovascular health by educating the public on cardiovascular risks.27 Life's Simple 7 includes rationale for a healthy cardiovascular lifestyle and how to manage blood pressure, control cholesterol, and reduce blood glucose; become more active and have a healthy diet; lose weight; and stop smoking. Finally, the most recent AHA guidance statements in 2018 and 2019 in relation to CVD prevention are based on treatment decisions for the individual patient according to cardiovascular risk estimation, but also advocate for healthy lifestyle across the life course of all individuals.28Uncertain Value of “High‐Risk” StrategiesThe value of screening for high‐risk CVD (“high‐risk” strategy) to reduce incidence of stroke and CVD on a population level has been questioned for several reasons.4, 25, 26First, by definition, the “high‐risk” strategy leaves out the people with low and moderate CVD risk who ultimately make up 80% of all stroke and heart attacks.29, 30 Therefore, the majority of the population at large, who contribute the majority of future incident CVD events, are not prioritized for recognition, education, and other prevention interventions.Second, labeling people as “low risk” may give them false reassurance that they are protected from stroke and heart attack, which may compromise their motivation to control their risk factors. This is particularly so for young people with high levels of risk factors and a high relative risk of stroke and CVD that requires at least intensive lifestyle advice, but in whom risk scores predict them to be at low absolute risk because of their age. Furthermore, clinicians often seek thresholds to trigger certain interventions. This concept is at odds with the fact that risk is a continuum, particularly for risk factors such as blood pressure and cholesterol, and there is no threshold at which certain interventions are automatically indicated. Therefore, it has been suggested that in communicating absolute CVD risk, categorization of people into low, moderate (mild), and high risk should be abandoned.31Third, with the exception of smoking, most behavioral risk factors that contribute a large proportion of stroke and CVD burden (unhealthy diet, sedentary lifestyle, and excessive alcohol intake),32, 33 are not included in the CVD risk screening systems. Independent genetic factors, which increase the risk of incident stroke by about one third,34 are also not included in CVD screening systems. Therefore, the ability of the CVD screening to detect, control, and monitor important lifestyle factors for stroke and CVD prevention is limited. However, it is acknowledged that risk prediction may improve in the future with multimodal strategies that include new technologies such as machine learning (which can construct mathematical functions via automated analyses of large training data sets and create models that may more accurately predict risk of stroke and CVD),35, 36, 37 although a recent systematic review showed no evidence of superior performance of machine learning over well‐established logistic regression for clinical prediction models.38Fourth, a microsimulation study39 evaluating CVD screening to reduce burden from CVD reported that universal screening seems less effective than population‐wide approaches in reducing CVD incidence, and emphasized that further research is needed to identify the best mix of population‐wide and risk‐targeted CVD strategies to maximize cost effectiveness and minimize inequalities.Fifth, CVD screening programs require considerable efforts and cost from society and individuals and are unlikely to be widely implemented in countries with limited resources unless they are effective or linked to existing effective programs.29 In some regions, such as Latin America, such “high‐risk” strategies are not used.40Sixth, there is no evidence that screening programs by themselves are effective in preventing stroke and CVD events. The Inter99 (Intervention 1999) randomized controlled trial (59 616 people aged 30 to 60 years followed for 10 years)13 was specifically designed to determine effects of screening for CVD risk and risk factors and lifestyle counseling on incidence of ischemic heart disease in the general population and found no significant difference between the intervention and control groups in the risk of ischemic heart disease (hazard ratio, 1.03, 95% CI, 0.94–1.13), stroke ( hazard ratio, 0.98; 95% CI, 0.87–1.11), combined ischemic heart disease and stroke ( hazard ratio, 1.01; 95% CI, 0.93–1.09), and total mortality ( hazard ratio, 1.0; 95% CI, 0.91–1.09). A subsequent Cochrane meta‐analysis12 of 15 randomized controlled trials comparing the effect of health checks (screening for >1 disease or risk factor) with no health checks in a total of 251 891 adults found there were no beneficial effects of general health checks over 1 to 15 years’ follow‐up for total mortality (risk ratio, 1.00; 95% CI, 0.97–1.03; I2=0%), CVD mortality (risk ratio, 1.05; 95% CI, 0.94–1.16; I2=65%), ischemic heart disease incidence ( risk ratio, 0.98; 95% CI, 0.94–1.03; I2=11%), or stroke incidence ( risk ratio, 1.05; 95% CI, 0.95–1.17; I2=53%).These data suggest that health checks with systematic CVD screening and counseling are not, in isolation, effective in practice. However, supplementing risk factor screening with behavioral counseling and pharmacological treatment as appropriate, and linkage to community programs has been shown to lower CVD risk over the next year by 10% in 31.8% (95% CI, 26.9%–36.6%) of individuals at moderate baseline risk and by 25% in 47.9% (95% CI, 41.2%–54.6%) of individual at high baseline risk, as predicted by the Framingham Risk Score.20Seventh, even if CVD screening systems are effective and identify all individuals in the population with a 10‐year CVD risk of ≥30% (6% of the population), and all of these individuals are appropriately treated, the incidence of major CVD is estimated to be reduced by, at most, 11%.41Finally, since many of the underlying causes of stroke and CVD are well established, identifiable, and controllable,42, 43, 44 according to Rose,1 there is not a major role for the “high‐risk” strategy for primary prevention of stroke and CVD, but more a complementary role to the more powerful population strategy.We are not advocating that screening for CVD risk be abandoned but that the “high‐risk” approach should not be the prime focus of public health policy for primary stroke and CVD prevention. It should be used as an adjunct to the population‐wide strategies and primarily for early detection of established risk factors,45 objective monitoring of progress of individuals in controlling their risk of CVD, and for determining thresholds for the pharmacological management and its intensity at the physician and individual level (eg, blood pressure and lipid‐lowering medicines, aspirin).46, 47, 48, 49, 50 In addition, to be widely used, such screening should be simple and inexpensive. For example, integrating screening for hypertension into routine medical examinations and related coverage by health insurance was recently recommended as a potentially cost‐effective tool for CVD prevention in Vietnam.51 Although recently there were concerns raised as to the low applicability of the thresholds for pharmacological treatments in resource‐poor countries,52 there is a danger of medicalization instead of focusing on lifestyle risk factor control.53 Health resources are too scarce to waste on proven ineffective and expensive screening strategies (that are not coupled with appropriate intervention) and, given the already huge and increasing stroke and CVD burden,6 the importance of the use of effective population‐wide primary stroke and CVD prevention strategies cannot be underestimated.In several countries, there are ongoing or intermittent media campaigns educating people about stroke and heart disease recognition for secondary stroke prevention, particularly stroke signs and symptoms that necessitate calling emergency services (eg, Face, Arm, Speech, Time [F.A.S.T.]) There is compelling evidence that F.A.S.T. campaigns result in increased ambulance dispatches and public stroke awareness, at least in the short term.54, 55 Importantly, the medical attention was sought by a bystander in nearly 90% of cases, suggesting the importance of mass‐media public education rather than focused programs in high‐risk groups for stroke.56 While the extensive 5‐year F.A.S.T.‐based public campaign in England cost $13.6 million and resulted in increased number of patients with major stroke who sought medical attention within 3 hours (odds ratio, 2.56; 95% CI, 1.11–5.90), it failed to improve the use of emergency medical services by people with transient ischemic attack and minor stroke (odds ratio, 0.79; 95% CI, 0.50–1.23).57 The authors called for campaigns that are tailored to transient and less severe symptoms. However, in a recent review of 30 studies on public stroke education, such campaigns were shown to be costly, and their efficacy was either limited (in terms of improving stroke outcomes) or not present.55 These results are in line with a systematic review of 11 studies examining effectiveness of the F.A.S.T. public campaign that showed that such campaigns may raise awareness of signs of stroke but have limited impact on behavior.58 It was also shown that stroke education of children at schools has proven feasible and efficient in the United States and Japan.55 Given the uncertainty about the long‐term sustainability of stroke awareness knowledge and cost‐effectiveness of F.A.S.T. public campaigns, especially for people with transient ischemic attack and minor stroke, further research into this important area of stroke education is needed. Clearly, primary and secondary stroke/CVD prevention campaigns should be viewed as complementary activities, with the priority given to primary stroke/CVD actions.Resetting Priorities Toward a Population‐Wide Strategy for Preventing Stroke and CVDFrom the public health perspective, the best ultimate measure of effectiveness of the primary stroke and CVD prevention interventions is incidence, both in absolute (number of new people affected by the stroke and/or acute myocardial infarction) and relative (rate per 100 000 per year) terms,59, 60 while prevalence of stroke/CVD risk factors in the population and global CVD/stroke risk estimates are important intermediate measures of the effectiveness.61 There is sufficient consistent, although modest, evidence of the effectiveness of population‐wide strategies to reduce the burden from stroke and CVD in the United States,62 Sweden,63 Finland,64, 65 and Japan66 to call for a review and resetting of priorities toward the population‐wide strategy for preventing stroke and CVD. Modeling studies suggest that any intervention that achieves even a modest population‐wide reduction in any major CVD risk factor would produce a net cost saving, as well as improving health.67 An 80% reduction in CVD among the working‐age population has been observed over 40 years in Finland concurrent with population‐wide changes in lifestyle and environment.68The population‐wide approach for primary stroke and CVD prevention with the emphasis on elimination of artificial trans‐fat, dietary sodium reduction, and effective treatment of elevated blood pressure was recently emphasized in the World Health Organization Global Hearts Initiatives69 and CVD initiative “Resolve.”70 Another important evidence‐based, feasible, and cost‐effective strategy to prevent stroke and CVD, with the focus on population‐wide prevention, is the World Health Organization “best‐buy” interventions.69, 71 Among 36 studies (608 940 participants), 19 reported on the effectiveness of tobacco‐related best buys, presenting good evidence for group interventions in reducing tobacco use but weaker evidence for interventions targeting individuals. There were fewer studies on smoking bans, warning labels, and mass media campaigns, and no studies on taxes or marketing restrictions. Fourteen of thebest buy interventions did not have any good evidence for effectiveness in low‐ to middle‐income countries. Observational evidence from the Nurses’ Health Study (71 243 women and 43 685 men free of CVD and cancer at baseline) suggested that controlling 5 lifestyle risk factors (smoking, physical activity, diet, alcohol consumption, weight) could reduce the risk of stroke by 47% (95% CI, 18–69) in women and by 35% (95% CI, 7–58) in men.72, 73Further population‐based observational evidence from the UK Biobank Study of 306 473 adults who were followed for a median of 7.1 years suggest that adherence to a healthy lifestyle (nonsmoker, healthy diet, body mass index <30 kg/m2, and regular physical exercise) could reduce the risk of stroke by up two thirds compared with an unfavorable lifestyle independent of genetic risk.34A modeling study has estimated that a 30% reduction in population‐wide sodium intake (World Health Organization recommended modest reduction) over 10 years could reduce the incidence of ischemic heart disease, ischemic stroke, and hemorrhagic stroke by about 7.3%, 7%, and 9.4%, respectively.74 Applying these estimates to the Global Burden of Disease 2017 data,75 it can be estimated that, globally, even this modest level of sodium intake reduction could annually prevent 776 500 cases of ischemic heart disease (95% uncertainty interval, 698 840–860 990), 541 660 cases of ischemic stroke (95% uncertainty interval, 486 580–607 430), and 394 800 cases of hemorrhagic stroke (95% uncertainty interval, 358 820–432 450).The increasing number of stroke cases throughout the world, particularly in low‐income countries, demands that we review our strategies and opportunities for optimal stroke prevention.60, 61 Geoffrey Rose always maintained the population and high‐risk approaches to prevention are not mutually exclusive but rather are complementary. We agree, but we are concerned that there has been a relative underutilization of population‐wide prevention strategies and increasing focus on “high‐risk” prevention strategies and that this imbalance may underpin suboptimal primary stroke and CVD prevention.31Funding of Primary PreventionTo be sustainable, primary stroke and CVD prevention strategies should not only be effective but sufficiently funded. Organization for Economic Cooperation and Development countries allocate <3% of their health spending on average to public health and prevention activities, and a large proportion of this funding (about 44%) is spent on less cost‐effective measures, such as healthy‐conditions monitoring, including CVD screenings.76 Just in England, annual costs of universal screening of 40‐ to 74‐year‐old adults for the risk of developing a chronic condition such as heart disease, stroke, kidney disease, type 2 diabetes mellitus, or dementia (NHS Health Check) amount to 165 million GBP.77 A recent microsimulation study to estimate the potential impact of this universal screening for primary prevention of CVD showed its inferiority compared with alternative strategies, which incorporate population‐wide approaches.39 In our opinion, a much greater proportion of public health funds, or access to other funds, is required to implement effective population‐wide strategies of prevention, minimize inequality in targets for prevention, and provide universal health coverage. However, the question is where to get additional funds for primary stroke and CVD prevention?As taxation on tobacco, salt, sugar, and alcohol is one of the most efficient ways to reduce their consumption and promote healthy behaviors78 (with the associated benefits for CVD and overall health at the population level)78, 79, 80, 81 and generate significant revenues for governments,78 we believe these revenues can and should be reinvested back into the public health sector and health research to improve the health of the taxpayers, including appropriate funding of primary prevention strategies for stroke, CVD, and other major noncommunicable diseases. Such uses of the tax revenue would also be important to ensure public acceptability of these taxes.82, 83 It was also suggested that organizations committed to CVD control in high‐income countries could provide some funding for resource‐poor countries to help them with the development and implementation of primary prevention strategies.84 The properly implemented primary prevention interventions will, in turn, generate significant additional cost savings from preventing diseases, which can be further used for improving well‐being of the population and various social programs. Unique political, social, and financial circumstances in a given country or region may require scaling of the population approach to successfully meet such challenges in the domain of prevention.ConclusionsPriority in the stroke and CVD primary prevention strategies should be given to the reduction of exposure to CVD risk factors of the whole population across the life course, regardless of the CVD risk, with the focus on behavioral and lifestyle risk factors (including tobacco use, unhealthy diet [excessive salt and sugar intake, lack of fruits and vegetables], physical inactivity, and the harmful use of alcohol), thus allowing an integrative approach that also targets other major noncommunicable diseases, such as dementia, diabetes mellitus, cancer, and pulmonary diseases.31 This is because nearly everyone is at lifetime risk of developing these diseases. This cluster of diseases and risk factors was prioritized by the World Health Organization and its Global Action Plan on noncommunicable diseases,85 and was also included in the 2011 United Nations Noncommunicable Disease Declaration, and the United Nations Post‐2015 Sustainable Development Goals.86 Focusing on the “high‐risk group” alone will be addressing just the tip of the iceberg (Figure). Therefore, a multisectoral total population approach is recommended as the priority.Download figureDownload PowerPointFigure 1. Theoretical models of causal pathways and benefits of population‐wide primary stroke and CVD prevention strategies for preventing other noncommunicable diseases. CVD indicates cardiovascular diseases.While advocating that the pendulum now has swung back toward population‐wide prevention strategies, we emphasize that optimal stroke and CVD prevention requires a complementary 2‐tiered population‐based and high‐risk approach, whereby measures and education about behavioral risk factors (diet, physical activity, alcohol and tobacco avoidance) are applied to the general population, and simple, inexpensive screening for a history of vascular disease and presence of modifiable vascular risk factors (particularly hypertension and smoking) is undertaken to identify those requiring the addition of prophylactic drug therapy to reinforced lifestyle and behavioral interventions (Table 3). Concurrently, global population exposure to improved social and environmental factors, including reduced exposure to air pollution, remain a priority for all. W" @default.
• W3002857025 created "2020-01-30" @default.
• W3002857025 creator A5000174970 @default.
• W3002857025 creator A5014800121 @default.
• W3002857025 creator A5019914929 @default.
• W3002857025 creator A5024693840 @default.
• W3002857025 creator A5031904244 @default.
• W3002857025 creator A5034467582 @default.
• W3002857025 creator A5061123357 @default.
• W3002857025 creator A5061402809 @default.
• W3002857025 creator A5067654386 @default.
• W3002857025 creator A5074548376 @default.
• W3002857025 creator A5075242638 @default.
• W3002857025 date "2020-02-04" @default.
• W3002857025 modified "2023-10-11" @default.
• W3002857025 title "What Is the Best Mix of Population‐Wide and High‐Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?" @default.
• W3002857025 cites W1681932403 @default.
• W3002857025 cites W1966628631 @default.
• W3002857025 cites W1971420153 @default.
• W3002857025 cites W1986019364 @default.
• W3002857025 cites W1993286003 @default.
• W3002857025 cites W2016680234 @default.
• W3002857025 cites W2019898061 @default.
• W3002857025 cites W2022355661 @default.
• W3002857025 cites W2022433742 @default.
• W3002857025 cites W2022503622 @default.
• W3002857025 cites W2029030193 @default.
• W3002857025 cites W2031296331 @default.
• W3002857025 cites W2032663271 @default.
• W3002857025 cites W2039855493 @default.
• W3002857025 cites W2048292526 @default.
• W3002857025 cites W2051106034 @default.
• W3002857025 cites W2051441592 @default.
• W3002857025 cites W2073790033 @default.
• W3002857025 cites W2082999713 @default.
• W3002857025 cites W2085980692 @default.
• W3002857025 cites W2096849439 @default.
• W3002857025 cites W2103064290 @default.
• W3002857025 cites W2108507145 @default.
• W3002857025 cites W2120723865 @default.
• W3002857025 cites W2126260349 @default.
• W3002857025 cites W2155121555 @default.
• W3002857025 cites W2156848121 @default.
• W3002857025 cites W2157962929 @default.
• W3002857025 cites W2163106819 @default.
• W3002857025 cites W2167595905 @default.
• W3002857025 cites W2170649441 @default.
• W3002857025 cites W2172010951 @default.
• W3002857025 cites W2196581383 @default.
• W3002857025 cites W2200715765 @default.
• W3002857025 cites W2236077962 @default.
• W3002857025 cites W2397694618 @default.
• W3002857025 cites W2398504757 @default.
• W3002857025 cites W2402599050 @default.
• W3002857025 cites W2412702708 @default.
• W3002857025 cites W2414777308 @default.
• W3002857025 cites W2424056036 @default.
• W3002857025 cites W2463406035 @default.
• W3002857025 cites W2490799204 @default.
• W3002857025 cites W2591218128 @default.
• W3002857025 cites W2599627323 @default.
• W3002857025 cites W2604448624 @default.
• W3002857025 cites W2751792491 @default.
• W3002857025 cites W2756248476 @default.
• W3002857025 cites W2782182435 @default.
• W3002857025 cites W2789136063 @default.
• W3002857025 cites W2791017618 @default.
• W3002857025 cites W2795438554 @default.
• W3002857025 cites W2795611399 @default.
• W3002857025 cites W2799589892 @default.
• W3002857025 cites W2811174095 @default.
• W3002857025 cites W2895023817 @default.
• W3002857025 cites W2898518163 @default.
• W3002857025 cites W2899773405 @default.
• W3002857025 cites W2901476346 @default.
• W3002857025 cites W2911368425 @default.
• W3002857025 cites W2912654919 @default.
• W3002857025 cites W2913876336 @default.
• W3002857025 cites W2913997948 @default.
• W3002857025 cites W2921112006 @default.
• W3002857025 cites W2921524827 @default.
• W3002857025 cites W2934399013 @default.
• W3002857025 cites W2938534754 @default.
• W3002857025 cites W2939223444 @default.
• W3002857025 cites W2942154415 @default.
• W3002857025 cites W2967692750 @default.
• W3002857025 cites W2984766121 @default.
• W3002857025 cites W3006057482 @default.
• W3002857025 cites W3021659692 @default.
• W3002857025 cites W4210347219 @default.
• W3002857025 cites W4254437263 @default.
• W3002857025 doi "https://doi.org/10.1161/jaha.119.014494" @default.
• W3002857025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7033901" @default.
• W3002857025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31983323" @default.
• W3002857025 hasPublicationYear "2020" @default.
• W3002857025 type Work @default.
• W3002857025 sameAs 3002857025 @default.
• W3002857025 citedByCount "25" @default.
• W3002857025 countsByYear W30028570252020 @default.
• W3002857025 countsByYear W30028570252021 @default.

• next